InMode Ltd logo

InMode Ltd(INMD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$13.27
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for INMD

11/13/2026: INMD (1-star) is currently NOT-A-BUY. Pass it for now.

InMode Ltd is a medical technology company specializing in energy-based minimally invasive and non-invasive aesthetic treatment solutions. The company's core strengths include proprietary radio frequency technologies like Morpheus8, exceptional gross margins, and a debt-free balance sheet with solid cash generation. Its primary growth opportunity centers on expanding aesthetic applications to address skin laxity driven by widespread weight-loss drug adoption. Key risks include revenue concentration in capital equipment, geopolitical manufacturing exposure in Israel, and sensitivity to macroeconomic cycles affecting elective procedures. The stock suits value-oriented investors seeking high profitability, while market participants should monitor quarterly equipment sales trends and international adoption metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile InMode features high historical profitability, recent top-line growth has moderated compared to its hyper-growth phase.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive upturn signal and renewed short-term price momentum.
Value investorStrong fitInMode trades at a low price-to-earnings multiple backed by significant cash reserves and strong free cash flow conversion.
Dividend investorWeak fitThe company does not pay a regular dividend, focusing instead on share buybacks and organic cash retention.
Low-risk investorMixed fitSmall-cap equity volatility and elective healthcare exposure introduce risk despite a debt-free balance sheet.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highSmall-cap aesthetic device stocks frequently experience sharp price fluctuations based on macroeconomic sentiment.
Valuation riskLowInMode trades at modest earnings multiples relative to its historical averages and cash levels.
Competition risk (aesthetic device competition)MediumIntense competition from emerging laser and RF device manufacturers could pressure pricing power.
Business qualityStrongThe company maintains exceptional gross and operating margins backed by proprietary technology.
Dividend incomeLow / noneIncome-focused investors receive no regular cash payout from the stock.
Execution riskMediumSustaining physician adoption and successfully commercializing new product lines is critical for future performance.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 763.61M USD
Price to earnings Ratio 11.15
1Y Target Price 14.67
Price to earnings Ratio 11.15
1Y Target Price 14.67
Volume (30-day avg) 563.6K shares
Beta 1.96
52 Weeks Range 12.72 - 16.67
Updated Date 11/15/2026
52 Weeks Range 12.72 - 16.67
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.19

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit -47.92%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
INMD receives a 4-star rating, supported by strong unit economics, and solid company fundamentals. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
INMD has solid overall fundamentals (4 stars), with solid financial health, soft growth momentum, and strong ownership. In FY2025 versus FY2024, strong cash generation (FCF margin 22.7%) and strong profitability (net margin 25.3%) are partially offset by negative earnings growth (-48.2%), negative revenue growth (-6.2%).

Financial Health Rating

★★★★★
INMD's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 81.9%). Overall financial-health metrics support a 4-star score.

Growth Momentum Score

★★★★★
INMD's growth profile is soft, with the least-weak measure being revenue growth at -6.2% FY2025 versus FY2024. By comparison, while earnings growth (-48.2%, negative) and free-cash-flow growth (-36.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 56.8% and approximately 83.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 13.22% supports management-shareholder alignment.

Top 5 Institutional Investors

Doma Perpetual Capital Management LLC 4.75%
Acadian Asset Management LLC 4.49%
BlackRock Inc 4.34%
Renaissance Technologies Corp 4.23%
MENORA MIVTACHIM HOLDINGS LIMITED 3.55%

Unit Economics (Per $1K Revenue)

★★★★★
INMD generates approximately $785 of gross profit, $230 of operating income, and $227 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins and solid cash conversion support the rating, although capital efficiency remains solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 14.95%

Quantitative Style Profile

★★★★★
INMD has a high-quality, liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedQuality TiltHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Capital EquipmentSales of multi-application aesthetic platforms like Morpheus8, BodyTite, and EvolveX to dermatology and plastic surgery practices.This is the primary upfront revenue engine when clinics purchase new treatment systems.
Consumables and ServicesSales of single-use treatment tips, treatment cartridges, and post-warranty service contracts.Provides recurring revenue streams as physicians perform repeat procedures for patients.
Geographic DistributionDirect sales in North America and Europe, supported by global international distribution partners.North America serves as the primary profit driver while international markets offer additional expansion upside.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-11
When Before Market
Estimate 0.322
Actual 0.37

Profitability

Profit Margin 19.95%
Operating Margin (TTM) 17.95%

Management Effectiveness

Return on Assets (TTM) 5.68%
Return on Equity (TTM) 11.42%

Valuation

Trailing PE 11.15
Forward PE 9.35
Enterprise Value 254.46M
Price to Sales(TTM) 2.04
Enterprise Value 254.46M
Price to Sales(TTM) 2.04
Enterprise Value to Revenue 0.68
Enterprise Value to EBITDA 3.82
Shares Outstanding 57.54M
Shares Floating 48.01M
Shares Outstanding 57.54M
Shares Floating 48.01M
Percent Insiders 13.22
Percent Institutions 56.84

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.